Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
复制标题
干扰素 α-2b 每日 3 次和沙利度胺治疗转移性肾细胞癌。
DOI：
--
复制
发表时间：
2003
影响因子：
45.3
通讯作者：
H. Joensuu
中科院分区：
文献类型：
--
作者：
M. Hernberg;P. Virkkunen;P. Bono;H. Ahtinen;H. Mäenpää;H. Joensuu
PURPOSE
The antiangiogenic effect of interferon (IFN) may improve with frequent dosing and by combination with other agents with antiangiogenic activity. To evaluate this potential, we treated patients with metastatic renal cell carcinoma (RCC) with frequently dosed IFN and thalidomide.
PATIENTS AND METHODS
Thirty patients were given IFN-alpha-2b 0.9 MU subcutaneously three times daily for 1 month and subsequently 1.2 MU tid unless serious toxicity was encountered. Thalidomide was first given 100 mg/d for 1 week and 300 mg/d thereafter. Sera were collected before and during treatment for serum vascular endothelial growth factor (S-VEGF) analyses performed using enzyme-linked immunosorbent assay.
RESULTS
The intention-to-treat response rate was 20% (95% CI, 6% to 34%) and response rate for assessable patients (n = 27) was 22% (95% CI, 6% to 38%). All responses were partial. In addition, 17 patients (63%; 95% CI, 45% to 81%) had stable disease for 3 months or longer. The median time to treatment failure was 7.7 months, and median survival time was 14.9 months. The most common cause of thalidomide discontinuation was neuropathy. S-VEGF levels decreased more in patients who responded to therapy compared with those in patients whose condition had stabilized or who had progressive disease (P =.036).
CONCLUSION
The combination of frequently dosed IFN-alpha-2b and low-dose thalidomide is feasible and active in advanced RCC, but the clinical benefit may remain small compared with that of IFN alone. Results from an ongoing phase III trial comparing IFN-alpha with or without thalidomide need to be analyzed before this combination can be recommended for use outside clinical studies.
登录
查看更多内容
干扰素-α介导的血管生成相关基因的下调和膀胱癌的治疗取决于生物剂量和治疗方案的优化。
DOI：
--
发表时间：
1999
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Slaton,JW;Perrotte,P;Inoue,K;Dinney,CP;Fidler,IJ
通讯作者：
Fidler,IJ
影响因子：
45.3
作者：
Motzer, RJ;Bacik, J;Mazumdar, M
通讯作者：
Mazumdar, M
影响因子：
11.2
作者：
T. Browder;C. Butterfield;B. Kräling;B. Shi;B. Marshall;M. O’Reilly;J. Folkman
通讯作者：
T. Browder;C. Butterfield;B. Kräling;B. Shi;B. Marshall;M. O’Reilly;J. Folkman
影响因子：
45.3
作者：
Little, RF;Wyvill, KM;Yarchoan, R
通讯作者：
Yarchoan, R
沙利度胺治疗晚期肾细胞癌患者的 II 期试验。
DOI：
10.1200/jco.2002.20.1.302
发表时间：
2002
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Motzer,RobertJ;Berg,William;Ginsberg,Michelle;Russo,Paul;Vuky,Jacqueline;Yu,Richard;Bacik,Jennifer;Mazumdar,Madhu
通讯作者：
Mazumdar,Madhu